Browsing: mepolizumab

Conditions

Nucala (mepolizumab) receives a positive reimbursement recommendation from CDA-AMC for adults with chronic obstructive pulmonary disease (COPD)

By 0

MISSISSAUGA, ON, Aug. 18, 2026 /CNW/ — GSK is pleased to announce that Nucala (mepolizumab) has received a positive reimbursement recommendation with conditions from Canada’s Drug Agency (CDA-AMC). The agency recommends that Nucala be reimbursed as an add-on maintenance treatment in adult patients with COPD characterized by raised blood eosinophils, inadequately controlled by the combination of an inhaled corticosteroid…